ClinicalTrials.gg
Status unknownNCT02670070Updated May 11, 2016

BE Study of the Combinations of Gemigliptin 50mg and Rosuvastatin 20mg in Comparison to Each Component Administered Alone

A Phase 1 interventional study of gemigliptin 50mg, rosuvastatin 20mg in Healthy, sponsored by LG Life Sciences. Status unknown at 1 site in Korea, Republic of. Open to male participants aged 19 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-05-11.

Sponsored by LG Life Sciences (part of LG Chem) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2016), so the status shown — last known as Enrolling by invitation — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
37
Allocation
Randomized
Ages
19 Years to 45 Years
Sex
Male
01

Study summary

This study is to evaluate the safety/tolerability and pharmacokinetics of the combinations of gemigliptin 50mg and rosuvastatin 20mg in comparison to each component administered alone in healthy male volunteers.

Read the detailed description

This study is to evaluate the safety/tolerability and pharmacokinetics(AUC and Cmax) of the combinations of gemigliptin 50mg and rosuvastatin 20mg in comparison to each component administered alone in healthy male volunteers.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

LG Life Sciences is the lead sponsor of 78 studies on the registry; none are open to participants now.

First submitted before LG Life Sciences became part of LG Chem.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 19 to 45, healthy male subjects(at screening)
  • between 18.0 - 27.0
  • FPG 70-125mg/dL glucose level(at screening)
  • Subject who totally understand the progress of this clinical trials, make decision by his free will, and signed a consent form to follow the progress.

Exclusion criteria

Exclusion Criteria:

  • Subject who has past or present history of any diseases following below.(liver including hepatitis virus carrier, kidney, Neurology,immunology,pulmonary,endocrine,hematooncology,cardiology,mental disorder.)
  • Subject who had GI tract disease or(ulcer, acute or chronic pancreatitis) surgery.(appendectomy, hernioplasty are not included)
  • Subject who had drug reaction.(Aspirin, antibiotics)
  • Subject who already participated in other trials in 2months
  • Subject who had whole blood donation in 2 months, or component blood donation in 1 month or transfusion in 1 month currently.
  • Heavy smokers.(>10 cigarettes per day)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
37 participants (actual)

Study arms

  • Active comparator
    Coadministration of G+R

    Coadministration of gemigliptin 50mg and rosuvastatin 20mg

    Drug: gemigliptin 50mg, rosuvastatin 20mg

  • Experimental
    Combination G/R

    Combination of gemigliptin 50mg / rosuvastatin 20mg

    Drug: gemigliptin 50mg, rosuvastatin 20mg

Interventions

06

What researchers measure

Primary outcomes

  1. AUClast, Cmax

    To evaluate AUClast/Cmax of gemigliptin and rosuvastatin

    Time frame: up to 72h post-dose

Secondary outcomes

  1. AUCinf

    To evaluate AUCinf of gemigliptin, LC15-0636 of gemigliptin metabolite and rosuvastatin

    Time frame: up to 72h post-dose

  2. Tmax

    To evaluate Tmax of gemigliptin, LC15-0636 of gemigliptin metabolite and rosuvastatin

    Time frame: up to 72h post-dose

  3. t1/2

    To evaluate t1/2 of gemigliptin, LC15-0636 of gemigliptin metabolite and rosuvastatin

    Time frame: up to 72h post-dose

  4. CL/F

    To evaluate CL/F of gemigliptin, LC15-0636 of gemigliptin metabolite and rosuvastatin

    Time frame: up to 72h post-dose

  5. metabolic ratio

    To evaluate metabolic ratio of gemigliptin, LC15-0636 of gemigliptin metabolite

    Time frame: up to 72h post-dose

  6. AUEC

    This parameter is been used to measure pharmarcodynamic characters of gemigliptin, the supression rate of DPP4 activity.

    Time frame: up to 72h post-dose

  7. Emax

    This parameter is been used to measure pharmarcodynamic characters of gemigliptin, the supression rate of DPP4 activity.

    Time frame: up to 72h post-dose

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, 110-744, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of Apr 2016 and a completion of Jun 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2015
First posted
Feb 1, 2016
Start
Mar 2016
Primary completionActual
Apr 2016
CompletionEst.
Jun 2016
Last update
May 11, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02670070
Lead sponsor
LG Life Sciences
Responsible party
Sponsor
First posted
Feb 1, 2016
Start date
Mar 2016
Primary completion
Apr 2016
Completion
Jun 2016 (estimated)
Last update
May 11, 2016

Study contacts

Kyung Sang Yu, MD, PhD
principal investigator · Seoul National University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemigliptin

Start the discussion